Lundbeck reports improved sales and profitability, beating forecasts

2 November 2016

Danish CNS specialist drugmaker Lundbeck (LUND: CO) saw its shares leap 7.8% to 231.90 Danish kroner this morning, after it raised its full-year revenue and profit forecasts after reporting stronger than expected third-quarter earnings.

Third-quarter 2016 revenue came in at 3.95 billion kroner ($587.5 million, beating Reuters poll of analyst’s forecasts of 3.71 billion kroner, Earnings before interest and taxes (EBIT)

For the first nine months of 2016 Lundbeck said revenues reached 11.47 billion, representing an increase of 6% compared to the same period last year. Revenue in the USA increased 33% (30% in local currency) to 6,035 million kroner.Revenue in international markets was unchanged (increased 4% in local currencies) at 2,988 million kroner. Revenue in Europe declined 25% (24% in local currencies) to 2,199 million kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK